Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label Study of Bortezomib (Velcade), Cladribine and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas

NCT00980395 is registered in ClinicalTrials.gov with University of Arizona as lead sponsor.

NCT NCT00980395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00980395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label Study of Bortezomib (Velcade), Cladribine and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas
Lead sponsor
University of Arizona
Phase
Phase 2
Overall status
Completed
Start date
July 7, 2009
Completion date
August 14, 2018
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

indolent lymphoma, lymphoma, mantle cell lymphoma, sll